COA Literacy Reading Peptide Test Results

First — get the terminology right

You’ll see two terms used interchangeably across vendor sites and creator content: “Certificate of Analysis” and “Certificate of Authenticity.” Only one is correct.

• Certificate of Analysis (COA) — the actual term. It’s the document a third-party analytical lab produces after running tests on the product: HPLC for purity, mass spectrometry for identity, LAL for endotoxins, sterility culture if applicable. The lab is analyzing what’s in the vial and reporting the result.
• Certificate of Authenticity — wrong term, but widely used by creator-tier content and some vendors. A “certificate of authenticity” describes provenance (this is a real Beatles autograph; this is genuine art). It tells you nothing about chemical composition. If a vendor calls their document a “Certificate of Authenticity,” that’s a small signal they’re not deeply familiar with the analytical-chemistry workflow.

Throughout this article, COA means Certificate of Analysis.

What a real peptide COA actually shows

A credible peptide COA from a credible third-party lab will contain at minimum:

1. The testing lab’s identity — name, address, contact info. Top labs in the space: Janoshik Analytical (Europe; widely regarded as the gold standard), Freedom Diagnostics (US-based; used by Alyve and other US-finishing vendors), Peptide Test (US-based).
2. A unique report number — verifiable by contacting the lab directly. Janoshik COAs in particular each carry a unique key that anyone can verify with the lab.
3. The compound identity — what the molecule actually is, confirmed by mass spectrometry. The molecular weight on the COA should match the published molecular weight of the compound. For example: BPC-157 = 1419.55 Da; Retatrutide = 4731.27 Da; TB-500 (full-length thymosin β-4) = 4921 Da. Identity confirmation is what tells you the powder in the vial is actually the compound on the label, not a different molecule entirely.
4. The purity percentage — measured by High Performance Liquid Chromatography (HPLC). OHM’s editorial position: anything below 99% should be a yellow flag; below 98% is a red flag. Lower purity means more impurities, which can be benign degradation products (mannitol fragments, water-loss adducts) or biologically active contaminants (truncated peptide sequences, residual synthesis chemistry like TFA salt, bacterial endotoxin).
5. The actual content amount — the milligram amount of peptide in the bottle. This is separate from the label number. A 10 mg label might test at 8.5 mg (underfill), 10.2 mg (close enough), or 14.7 mg (significant overfill). All of these tell you something — and overfill in particular has direct titration-safety implications, which we cover below.
6. Sterility testing — culture-based confirmation that no microbial contamination is present. Important for injectable preparations.
7. Endotoxin (LAL) testing — confirmation that bacterial-cell-wall debris (lipopolysaccharide / LPS) is below regulatory threshold. Genuine safety signal — endotoxin contamination in injectables produces real pyrogenic reactions (fever, chills, hypotension, in severe cases sepsis-like presentations). Some creator-tier voices dismiss endotoxin testing as overcaution; OHM does not agree with that dismissal — the FDA regulates endotoxin limits in injectable pharmaceuticals for a reason, and gray-market vials are produced in environments with much less rigorous bioburden control than regulated pharmaceutical manufacturing.
8. Batch identifier — production lot number, which should match the batch label on your actual vial.
9. (Ideally) a photograph of the tested bottles — including the cap color and seal color. This is where the “match your bottle to the tested batch” trick lives — see the next section.

The cap-and-seal color matching trick — your most important verification

This is the single highest-leverage verification step the consumer can perform, and almost nobody knows about it.

Manufacturers use different cap colors and seal colors for different production batches as an internal batch-tracking convention. Standard practice is that a manufacturer doesn’t repeat a cap/seal color combination within a year. The COA, if it includes a photograph of the tested bottle, will show the exact cap color and seal color of the batch that was actually analyzed in the lab.

When your bottle arrives, compare its cap color and seal color to the photo on the COA.

• If they match: the COA is plausibly for your batch. You still need to verify the COA’s report number with the testing lab, but you’ve cleared the first check.
• If they DON’T match: you have potentially received a vial from a different batch than the one tested. The published COA tells you nothing about what’s in your specific vial. Email the vendor and demand the COA for your batch number, or the COA for the cap-and-seal color you actually received. If the vendor can’t produce one, that’s a real red flag.

Some labs charge vendors extra to include the bottle photograph on the published COA. That’s a workflow detail worth knowing about: if a vendor’s COA doesn’t have a bottle photo, the cap-color verification step isn’t available to you and you have to verify the batch through other means (the batch number on the vial matching the batch number on the COA, the vendor sending you a fresh COA on request).

Underfill vs overfill — implications for titration math

A bottle labeled “10 mg” might not actually contain exactly 10 mg of peptide. Honest vendors will tell you on the COA what the actual content is. Three patterns:

• Underfill (actual content < label): vial reads 10 mg, contains 9.2 mg. Safer from a titration standpoint. If you reconstitute and dose by the label number, you’ll under-dose, not over-dose. Easy to detect: your protocol effect should be modestly weaker than expected.
• Close-enough (actual content within ~5% of label): vial reads 10 mg, contains 10.3 mg. Functionally indistinguishable from label dosing. The most reasonable target for honest manufacturing.
• Overfill (actual content > label): vial reads 10 mg, contains 12.1 mg or higher. This is where titration safety gets dangerous. A “0.5 mg start dose” calculated off the label is actually 0.6+ mg in the syringe. For Retatrutide specifically, this can push a first-time user from “tolerable nausea” into “ER visit” territory. Two documented examples:
  • A 10 mg Retatrutide bottle from a major vendor (Modern Amino, per the Peptide Critic source video) averaged 12.113 mg actual — a 20% overfill. First-time titrators dosing off the label number would have hit GI events they wouldn’t have hit at the intended dose.
  • A research-grade Retatrutide vial labeled 60 mg, sent for independent testing by fitness creator Ryan Humiston in 2026, came back at 108 mg actual — 180% of label claim. A 0.5 mg start dose calculated off that bottle would actually be 0.9 mg, well into severe-GI-event territory for many users.

The overfill pattern is widespread because vendors prefer to err on the side of giving the customer more rather than less — but the customer’s titration math doesn’t account for it unless the customer looks at the actual COA content number and adjusts the reconstitution accordingly. This is one of the single most important practical reasons to actually read the COA, not just see that one exists.

For non-titration-sensitive compounds (GHK-Cu, BPC-157, TB-500), overfill mostly just means you got more product for your money. For titration-sensitive compounds (any GLP-1 receptor agonist, anything with a meaningful dose-response side-effect tail), overfill is a real safety risk.

The Janoshik failure-rate anchor — why this matters at the population scale

The numbers tell the story.

Janoshik Analytical reported that in 2024, 43% of peptides submitted for testing failed to meet their label purity claims. Lower-tier vendors showed actual purities of 71–91% on products marketed as 99%+. That’s not a “few bad actors” pattern. Almost half of the research-peptide market that goes through Janoshik’s screening fails the basic purity standard.

Independent gray-market peptide testing campaigns have reported similar patterns. Plasencia & Sheffer’s 2026 empirical testing (referenced elsewhere in the OHM library) found roughly 25% of independently-purchased gray-market vials underdosed, mislabeled, or contaminated. The 2017 JAMA SARMs study (Van Wagoner et al., PMID 29183075) tested 44 SARM products marketed online; 9% had no active compound, 25% contained substances not listed on the label, and only 41% had the labeled amount of active compound. Different research chemicals, similar supply-chain failure profile.

The OHM editorial position remains unchanged: the verified-vendor + third-party-COA framework is what closes the supply-chain gap. Without it, the customer is playing the 43% failure rate. With it, the customer is paying a markup that buys actual third-party verification of what’s in the vial. That value tradeoff is real.

Testing labs to trust (and one historical fake to know about)

Trust:

• Janoshik Analytical — Europe-based, widely regarded as the gold standard in the gray-market peptide testing space. Conducts HPLC purity, mass spec identity confirmation, sterility, and endotoxin (LAL) testing. Reports have unique verifiable identifiers. Used by many top-tier research-peptide vendors.
• Freedom Diagnostics — US-based testing lab. The lab Alyve uses for its COAs across its catalog. Provides HPLC-UV purity and LC-MS identity confirmation.
• Peptide Test — US-based, well-known in the research-peptide space.
• (Cautiously) other independent analytical labs that publish their methodology, charge per-test fees rather than work as captive vendor partners, and produce verifiable unique report numbers.

Historical fake worth knowing about:

• “Freedom Pharmacy” — distinct from Freedom Diagnostics. Per multiple consumer-protective sources, “Freedom Pharmacy” was a fake testing-lab name used by a Chinese reseller operating out of Southern California to produce Photoshopped fake COAs. Now apparently defunct, but worth flagging as a real example of a fake-COA fraud pattern: a real-sounding lab name, a professional-looking COA PDF, and no actual lab behind it.

Verification mechanic: for any COA you receive, the gold-standard verification is contact the testing lab directly with the unique report number on the COA and ask them to confirm it’s a real report. Janoshik in particular has a workflow for this and will verify whether a given report number corresponds to a real analysis they conducted. If a “lab” doesn’t respond to verification requests or doesn’t have a contact channel for verification, that’s a strong signal the COA is fake.

Step-by-step: how to actually use Janoshik's public verification tool

Janoshik publishes a public verification tool on their website that lets anyone confirm whether a specific test result was actually performed by them — and lets you open the real report to compare against what a vendor is showing you. This is the single most actionable customer-protection step in the entire research-peptide vetting workflow. It takes about 90 seconds, works on a phone or desktop, and catches the most common fake-COA attack pattern.

The attack pattern this verification defeats — the Photoshopped-header scam: a fraudulent vendor takes a REAL Janoshik COA from someone else’s actually-tested product, opens it in Photoshop, and modifies only the company / manufacturer name at the top of the document. All the underlying test data (purity numbers, lot codes, batch identifiers) stays unchanged because they’re trying to look like they own a real verified result. The customer who doesn’t verify sees a credible-looking COA from a real lab → buys → gets junk product, gets nothing, or gets something that could harm them. This scam works precisely because Janoshik’s actual purity numbers ARE real on the document — only the header has been changed.

The 7-step verification workflow:

1. Locate the Task Number on the COA. It appears near the top, usually a 4–6 digit number labeled “Task Number” or similar.
2. Locate the Unique Key on the COA. It appears near the bottom — a string of 8–12 letters and numbers.
3. Go to janoshik.com and click “Verify.” The verification page is accessible from the main site navigation.
4. Enter both the Task Number and the Unique Key into the verification form on Janoshik’s site.
5. The system returns one of two responses:
   • “This test is in our database” — confirmation that Janoshik actually performed this test. The system then lets you open the REAL report.
   • No match / error — the COA is not in Janoshik’s database. The COA is fake. Do not buy.
6. CRITICAL STEP if the test is in the database: open the real report and put it SIDE BY SIDE with the COA the vendor is showing you. Compare the company/manufacturer name in the header, the product name and batch number, the purity percentage, the lot numbers, and any other identifying information.
7. If the company name on Janoshik’s real report differs from the company name on the vendor’s COA, you have caught a Photoshopped-header scam. The vendor is using someone else’s real test result with their own name pasted on top. Don’t buy from them, and consider reporting the listing wherever you found it.

This workflow specifically catches the Photoshopped-header attack pattern that is overwhelmingly the most common COA fraud in Facebook groups, Discord channels, WhatsApp peptide-vendor communities, and Telegram. A vendor that has a real Janoshik COA for their actual product will pass this verification cleanly; a vendor running the Photoshopped-header scam will fail it immediately.

Finnrick — the free-testing alternative (and a representation correction)

Alongside Janoshik, the other major community-trusted peptide testing lab is Finnrick Analytics (correct spelling — with a ‘ck’; some earlier community content including some early OHM KB references used “Finnrik” without the ‘ck’, which is incorrect). Finnrick is US-based, operating out of Texas at finnrick.com. Their model is meaningfully different from Janoshik’s:

• Free testing. Finnrick is a community-supported project funded by donations. They test peptide samples for free. You can ship samples to them in Texas, and they’ll also source and test specific vendor products on request.
• 263 vendors rated, 8,687 samples tested across 15 different peptides per their public site (as of mid-2026).
• Browsable public vendor list at finnrick.com/vendors. You can search whether a specific vendor is in their database before purchasing.
• 0–10 scoring system, NOT A–F grading. Finnrick scores each tested sample 0–10 across three dimensions: purity (0–4 points), quantity accuracy vs label (0–4 points), and batch info quality (0–2 points). A correction worth flagging: some community content (and some earlier OHM KB references) translates Finnrick’s 0–10 scoring into an informal A–F grading scale. The lab itself uses 0–10, and we should use their actual scale.

How to use Finnrick for vendor verification:

1. Go to finnrick.com/vendors
2. Search for the vendor you’re considering
3. If they’re listed, you see Finnrick’s score for their tested product(s) — including the breakdown across purity, quantity, and batch info
4. If they’re not listed, that’s not automatically disqualifying — Finnrick can’t test every vendor — but it’s a signal worth noting alongside the rest of your vetting
5. If you want a specific product tested that’s not in their database, you can request testing or ship a sample yourself

Finnrick + Janoshik together — the comprehensive verification stack: the gold-standard customer move is to (a) check if the vendor is in Finnrick’s vendor list and what their score is, AND (b) verify any Janoshik COA the vendor publishes using the 7-step workflow above. Two independent lab verifications + your own cap-and-seal color match against the COA bottle photo = approximately the strongest verification a research-peptide customer can perform without their own analytical lab.

On the endotoxin question — a quick honest detour

Some creator-tier voices in the peptide space dismiss endotoxin (LAL) testing as unnecessary overcaution or “boogeyman myth” framing borrowed from broader inflammation discourse. OHM does not agree with that dismissal.

Endotoxin contamination in injectable preparations is a real safety concern. Bacterial endotoxin (lipopolysaccharide / LPS) is the outer-membrane component of gram-negative bacteria, and even small amounts injected systemically produce documented pyrogenic reactions: fever, chills, hypotension, tachycardia, in severe cases sepsis-like presentations. The FDA regulates endotoxin limits in injectable pharmaceuticals for a reason, and the LAL (Limulus Amebocyte Lysate) test is the regulatory standard for measuring it. Janoshik and other credible peptide testing labs include LAL testing for this reason.

The gray-market peptide supply chain produces vials in environments with substantially less rigorous bioburden control than regulated pharmaceutical manufacturing. Endotoxin contamination is a meaningful concern in this space — not a manufactured concern. A COA that includes endotoxin testing is more valuable than one that doesn’t, and a vendor that dismisses endotoxin concerns should be downweighted accordingly.

Note: this is distinct from the broader (and contested) discussion of gut-derived endotoxin / LPS as a driver of systemic inflammation, which appears in various functional-medicine and biohacker content. That’s a separate topic. The endotoxin concern in injectable peptides is a settled pharmaceutical-quality issue.

Practical action steps for the customer

If you’ve bought a peptide and want to verify what you have:

1. Confirm the vendor publishes a COA for the batch you received. Check that the batch number on your vial matches the batch number on the COA. If it doesn’t, demand the COA for your batch.
2. Check the cap color and seal color on your vial against the photo on the COA. If they don’t match, demand the COA for the cap/seal color you actually received.
3. Check the testing lab named on the COA. Is it Janoshik, Freedom Diagnostics, Peptide Test, or another verifiable independent lab? Or is it a name you can’t find with a web search?
4. Verify the unique report number with the testing lab directly if possible. Janoshik in particular has a verification workflow. A real lab will confirm; a fake one won’t respond.
5. Read the actual content number, not just the label number. Adjust your reconstitution math if the actual content differs meaningfully from the label.
6. Check the purity percentage. Anything below 99% deserves a yellow flag; below 98% deserves a red flag (especially when combined with elevated content amount, which can indicate degradation + excess mannitol or worse).
7. Check for sterility and endotoxin testing. Both should be present for injectable preparations.
8. If anything doesn’t add up, don’t inject the product. The downside of wasting one purchase is far smaller than the downside of injecting a fake or contaminated product into your bloodstream.

How OHM's verified vendors handle this

OHM’s recommended vendors — Alyve, AminoClub, BioLongevity — all publish third-party COAs as part of their standard practice. The COA discipline isn’t a marketing layer; it’s the substance of the value proposition. Specific cross-references:

• Alyve uses Freedom Diagnostics Testing for HPLC-UV purity and LC-MS identity confirmation across its catalog. Recent examples: Retatrutide 10 mg vial tested at 99.01% purity, net content 10.47 mg (lot RET750); 20 mg vial tested at 99.13%, net content 23.96 mg (lot RET602). Identity-confirmed as Retatrutide in both cases.
• AminoClub publishes a public COA library on every product page, generally testing with Janoshik or comparable.
• BioLongevity publishes COAs but note the existing OHM editorial caveat: per Finnrik’s A–F grading scale, BioLongevity’s BPC-157 graded E and Retatrutide graded C in independent testing, which is why OHM routes BPC-157 and Retatrutide purchases away from BioLongevity and toward Alyve / AminoClub. Their other compounds (Semax, Selank, Epithalon, Kisspeptin-10) tested at acceptable grades.

The framework above lets you verify any of these claims yourself. That’s the point — OHM teaches the framework, the framework verifies OHM’s vendors, and trust grows from real verification rather than from marketing.

The contrarian "COAs are killing the industry" argument — engaged honestly

There’s a serious industry-insider counter-argument to the entire COA-literacy framework this article presents, and it deserves to be engaged with directly rather than dismissed. The strongest version of the argument (Holyfield 2026 most prominently): the consumer-facing COA culture is creating a regulatory paper trail that pharmaceutical companies (Eli Lilly, Novo Nordisk) will weaponize to pressure FDA enforcement, ultimately shutting down access to affordable research peptides. Every public COA, the argument goes, is essentially a vote for the FDA to place that vendor under extreme scrutiny. The transparency consumers are demanding is creating the evidence trail that will end their cheap-peptide access. The industry is, in this framing, eating itself.

OHM’s position is that this argument is partially true and partially overstated.

Where it’s partially true: the FDA Category 2 (“do not compound”) decision in November 2024 for ~20 peptides including BPC-157 was substantially the result of pharma + FDA convergence on enforcement against compounding lanes that compete with patented products. Pharmaceutical industry pressure on FDA to enforce against compounding lanes that erode their revenue is a documented dynamic. The competitive dynamics around COA publishing — where small mom-and-pop vendors can’t afford the testing larger vendors weaponize as differentiation — are real industry-insider observations.

Where it’s overstated: the specific mechanism — that publicly published Janoshik COAs are the FDA’s enforcement vector — does not hold up under scrutiny. FDA enforcement actions in the research-peptide space don’t trace back to COA publication. They trace back to direct marketing claims targeting human consumption, adverse event reports, pharma-initiated complaints, customs seizures at ports, and the documented regulatory-process safety + identification + immunogenicity concerns that drove the Category 2 decision. A vendor that publishes a Janoshik COA showing 99.2% purity isn’t materially more enforceable than one that publishes no COA at all.

What the argument essentially asks the customer to do: choose between (a) verifying what they’re injecting and (b) preserving the research-chemical regulatory gray zone for the broader industry. OHM rejects this as a false choice. Verification protects the individual customer from the most common gray-market failure modes (mislabeled vials, contamination, fake product). It does not measurably move the regulatory-enforcement needle against the broader industry. The customer benefit of COA verification is real and concrete; the alleged regulatory cost is speculative and overstated.

That said, the underlying industry-insider observation about competitive dynamics is real. The COA-marketing-arms-race creates a barrier-to-entry that benefits larger, better-capitalized research-peptide vendors at the expense of smaller ones. Reasonable people can read that differently. The OHM editorial position is that customer protection trumps industry competitive dynamics on this particular question — but we surface the counter-argument honestly so the customer can make their own call. That’s how this site works.

A related vendor-side framing worth knowing about: some vendor founders push back on the “gray market” terminology itself as overbroad — arguing that properly-labeled, third-party-tested, HPLC-verified research-grade compounds shouldn’t be lumped together with counterfeit or unregulated products under the same “gray market” label. There’s a partial linguistic point in that critique. But the regulatory gray-zone reality the term points to is accurate — “research use only” is a real legal classification AND a legal fiction widely understood by vendors and customers to be such. Both can be true simultaneously. OHM uses “gray market” to refer to the regulatory positioning of research-chemical peptide commerce overall, not as a quality judgment on any specific vendor. A verified vendor with documented COAs IS operating in the regulatory gray zone; that’s a structural reality, not a slur.

For the deeper global manufacturing context — where peptides are actually made, what “Made in USA” really means on a research-peptide label, and the OHM “third option” customer pathway — see Where peptides are actually made — the global manufacturing reality.

Cross-references in the wiki

• Retatrutide — for the Retatrutide-specific titration-safety implications of overfill, plus the supply-chain reality section.
• The mainstream-medicine skeptical position — what the other side actually says — the mainstream-medicine view explicitly converges with OHM on the supply-chain question. Both camps point to the JAMA SARMs analog data.
• Where peptides are actually made — the global manufacturing reality — the global manufacturing-geography deep-dive that engages Holyfield’s strongest arguments honestly. The COA literacy framework in this article is the verification half; the manufacturing-geography article is the supply-chain half.
• The where-to-buy page on the OHM site — for the actual vendor-routing recommendations.

---

Last updated: 2026-06-20. Created as a customer-protective content piece anchored on the verified Janoshik 2024 failure-rate data and the COA walkthrough content in two source videos (Peptide Critic + Reta Unfiltered with David). The article will become the source for a future Peptides 101 article (“How to Read a Peptide Certificate of Analysis”). All practitioner content paraphrased per Doctrine #3 — no verbatim quotes. The contrarian “endotoxin is a Huberman boogeyman myth” framing surfaced from the source video has been explicitly NOT propagated — OHM’s editorial position is that injectable endotoxin contamination is a real safety concern with regulatory grounding.